Tagged: neuroscience
30 results
Axonis Therapeutics
Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class oral small-molecule medicines that target KCC2, a chloride transporter that acts as the brain's master regulator of inhibitory neurotransmission. Spun out of research from Boston Children's Hospital, Harvard Medical School and Universite Laval, Axonis is advancing its lead candidate AXN-027 - a first-in-class KCC2 potentiator - toward clinical proof of concept in epilepsy, chronic pain and other CNS disorders, backed by an oversubscribed $115 million Series A closed in 2024.
Coro Health
Coro Health is an Austin-based healthcare technology company that delivers clinically proven therapeutic music and multi-faith spiritual programming through a fully licensed streaming service built specifically for care settings. Its flagship MusicFirst platform uses a patented Music Prescription Builder - designed by music therapists, neuroscientists, and music designers - to generate individualized programs shown in peer-reviewed trials to reduce depression and agitation in dementia and long-term care residents. The company also offers FaithFirst multi-faith content and EnrichFirst entertainment, reaching more than a million annual users across thousands of senior living communities and hospitals in the U.S. and Canada.
David Schofman
David Schofman is the CEO and co-founder of Coro Health, an Austin-based company that builds therapeutic music and multi-faith spiritual streaming programs for senior living communities, hospitals and hospices. A serial entrepreneur who built one of the first online golf retail businesses in the 1990s and later ran global ecommerce for Callaway Golf, Schofman turned to health technology in 2008, translating research on music and the brain into a subscription platform now used across thousands of care communities in the US and Canada.
Neurable
Neurable is a Boston-based neurotechnology company building non-invasive brain-computer interfaces (BCIs) that fit inside everyday consumer hardware. Its AI cleans and interprets EEG brain signals captured by soft sensors embedded in products like the MW75 Neuro headphones, translating brain activity into real-time measures of focus, mental fatigue and cognitive recovery. Spun out of University of Michigan research, Neurable aims to make understanding your own brain as natural as checking your step count - starting with headphones and expanding into gaming and enterprise wearables.
NeuShen Therapeutics
NeuShen Therapeutics is a clinical-stage biotech developing novel small-molecule and gene-therapy treatments for central nervous system disorders such as schizophrenia, depression and epilepsy. Founded in 2021 by Joan Huaqiong Shen, MD, PhD, and headquartered in Shanghai with an R&D center in the Boston area, the company runs a pipeline led by NS-136, a selective M4 receptor positive allosteric modulator for schizophrenia, and NS-041, a highly selective KCNQ2/3 activator for epilepsy and depression.
Presidio Medical, Inc.
Presidio Medical is a clinical-stage medical device company in San Mateo, California, developing a proprietary Ultra Low Frequency (ULF) neuromodulation platform. By delivering very low frequency biphasic electrical currents through leads implanted in the epidural space, Presidio's spinal cord stimulation system reversibly blocks the conduction of pain signals along nerves without damaging tissue. Its first target is chronic nociceptive low back pain, a large and underserved indication with no approved SCS therapy. Backed by Deerfield Management and others, the company raised a $72M Series C in 2023 and received FDA IDE approval in 2025 to run its global pivotal FULFILL trial.
ProJenX
ProJenX is a New York City clinical-stage biotechnology company developing prosetin, a first-in-class, oral, brain-penetrant MAP4K inhibitor for amyotrophic lateral sclerosis (ALS) and other neurodegenerative brain diseases. Spun out of a two-decade collaboration between the nonprofit Project ALS and Columbia University researchers, ProJenX is built on the discovery that inhibiting MAP4 kinases protects motor neurons across multiple patient-derived stem cell models of ALS. The company is running the PRO-101 Phase 1b trial in people living with ALS.
Stellaromics Inc.
Stellaromics is a Boston-based spatial biology company building tools that map gene expression in three dimensions inside intact tissue. Spun out of the labs of Karl Deisseroth (Stanford) and Xiao Wang (MIT/Broad Institute), the company commercializes its Pyxa platform, which uses proprietary STARmap and RIBOmap chemistry to deliver multiplexed 3D spatial transcriptomics and translatomics in tissue sections up to 100 microns thick at subcellular resolution. It targets researchers in neuroscience, oncology and immunology who need to preserve native tissue architecture rather than rely on flat 2D thin-section methods.
Vertero Therapeutics, Inc.
Vertero Therapeutics is a clinical-stage biotechnology company in Woburn, Massachusetts, developing oral small-molecule drugs for neurodegenerative diseases by targeting causative drivers in the body's periphery - primarily the gut - rather than only the brain. Formerly Axial Therapeutics, the company rebranded as Vertero in October 2025. Its lead candidate, VT-5006, is a gut-selective small molecule for Parkinson's disease that targets CsgA, a bacterial protein linked to protein aggregation and neuroinflammation, and is entering Phase 1 trials.
Joan Shen
Joan Huaqiong Shen is the founder and CEO of NeuShen Therapeutics, a clinical-stage biotech with R&D centers in Shanghai and Boston that develops treatments for psychiatric and neurological disorders. A physician-scientist trained in psychiatry and neurology, she spent decades leading central-nervous-system drug programs at Eli Lilly, Wyeth, Pfizer, Hengrui and Johnson & Johnson before running R&D and serving as CEO at I-Mab Biopharma, where she took the company public on Nasdaq and struck a global partnership with AbbVie. In 2026 NeuShen closed a Series A+ round led by Lilly Asia Ventures as its lead compound NS-136 advanced into Phase 2 trials.
Joanna Stanicka
Joanna Stanicka is the co-founder, president and CEO of Axonis Therapeutics, a Boston clinical-stage biotech developing first-in-class oral medicines that target the brain chloride transporter KCC2 to treat epilepsy, neuropathic pain and spinal cord injury. A Harvard-trained neuroscientist who began her career in cancer biology in Ireland, she moved from the bench to the boardroom, taking Axonis from a Boston Children's Hospital discovery to a company that raised a $115 million Series A in 2024 and pushed its lead drug, AXN-027, into first-in-human trials.
Kelvin Chan
Kelvin Chan is a co-founder of Nirvana, a New York healthtech company that uses machine learning and data science to turn insurance verification and cost estimation into something providers and patients can trust. He leads product and serves as president. A Columbia-trained neuroscientist who spent years building enterprise data software at Enigma, Chan started Nirvana in 2019 after a frustrating personal experience trying to find out whether his insurance would cover a therapist. The company has raised $24.2M in Series A funding led by Northzone and now powers eligibility checks across digital health platforms and provider offices nationwide.
Muse by Interaxon Inc.
Muse, made by Toronto-based Interaxon Inc., is a brain-sensing headband that turns clinical-grade EEG into a consumer wearable. First shipped in 2014, Muse reads your brainwaves and, through a companion app, gives real-time audio feedback to guide meditation, track sleep, and train focus. The company has since layered on fNIRS and SpO2 sensing (Muse S Athena, 2025) and an AI brain-health platform trained on more than a billion minutes of EEG data, positioning Muse at the intersection of consumer wellness and clinical neuroscience.
Therini Bio, Inc.
Therini Bio is a clinical-stage biotechnology company developing fibrin-targeting immunotherapies for neurodegenerative and retinal diseases driven by vascular dysfunction. Founded in 2019 on the neurovascular research of Dr. Katerina Akassoglou at UCSF and the Gladstone Institutes, the company's lead antibody THN391 selectively blocks fibrin's inflammatory epitope to halt chronic neuroinflammation without interfering with normal blood clotting. Backed by roughly $145M in total funding from investors including Eli Lilly, Sanofi Ventures, Merck's MRL Ventures and the Dementia Discovery Fund, Therini is advancing THN391 into Phase 1b trials for Alzheimer's disease and diabetic macular edema.
Ramses Alcaide
Dr. Ramses Alcaide is the co-founder and CEO of Neurable, a Boston-based neurotechnology company building brain-computer interfaces disguised as ordinary headphones. A neuroscientist trained at the University of Washington and the University of Michigan, he turned a decade of EEG research into the MW75 Neuro, a Master & Dynamic collaboration that reads brainwaves to help wearers focus. Neurable has raised roughly $49M, closed a Series A in late 2025, and unveiled a HyperX gaming headset at CES 2026.
Arcade Therapeutics
Arcade Therapeutics is a New York-based digital therapeutics company that builds clinically validated mobile games to treat mental illness. Founded by healthcare entrepreneur Raj Amin and neuroscientist Tracy Dennis-Tiwary, the company embeds a research-backed technique called attention bias modification into engaging games, starting with StarStarter for anxiety. Its lead prescription product, ABM-01, is pursuing FDA submission as one of the first game-based treatments for social anxiety disorder, with a pipeline extending to depression, addiction, and other conditions.
Attune Neurosciences, Inc.
Attune Neurosciences is a San Francisco-based, clinical-stage medical device company building what it calls the first wearable, non-invasive focused-ultrasound system for deep brain therapy. Its investigational headband, ATTN201, uses low-intensity transcranial focused ultrasound (tFUS) to reach precise deep-brain targets - like the central medial thalamus - while recording EEG and head movement, aiming to treat sleep and wake disorders, depression, addiction recovery, and other neurological and psychiatric conditions without drugs or surgery.
Impairment Science, Inc.
Impairment Science, Inc. is a Cambridge, Massachusetts neuroscience company behind DRUID, a smartphone app that measures cognitive and motor impairment from any cause - cannabis, alcohol, fatigue, medication, or illness - in about one to three minutes. Conceived in 2016 by longtime UMass Boston psychology professor Dr. Michael Milburn and incorporated in 2018, DRUID scores a person's reaction time, decision-making, hand-eye coordination, and balance against their own sober baseline. It is the only impairment technology with three published, peer-reviewed studies validating its accuracy, including research led by Johns Hopkins School of Medicine faculty. The company now sells DRUID Enterprise, a cloud portal that lets employers in construction, mining, EMS, and other safety-critical industries run fitness-for-duty checks without a breathalyzer or urine sample.
NeuroAge Therapeutics
NeuroAge Therapeutics is a San Francisco tech-bio company that measures how old your brain actually is - and tries to make it younger. Founded in 2022 by physician-scientist Dr. Christin Glorioso, the company's flagship NeuroAge Test blends brain MRI, cognitive games, proprietary RNA blood biomarkers, and genetic screening into a single 'brain age' score that aims to flag dementia risk up to 30 years before symptoms appear. The longer-term goal is bolder: small-molecule drugs that reprogram aging neurons back toward a younger state.
Roga
Roga is a neurotech company building a non-invasive vagus nerve stimulation wearable paired with an AI-guided meditation app to reduce stress and burnout. Founded by two people who each managed clinical anxiety, the discreet behind-the-ear device sends gentle electrical pulses to calm the nervous system, while the companion app personalizes meditation and tracks progress. Based in Los Angeles and Toronto, Roga sells direct to consumers and to employers running workplace wellness programs.
Wonder Sciences
Wonder Sciences is a Los Angeles-based mental health and research company reengineering psychiatric care through psychedelic medicine, clinical research, and AI. Best known for its consumer brand Wondermed - an at-home, low-dose ketamine-assisted telehealth protocol for anxiety and depression - the company is building an AI-native clinical operating system that fuses medication, therapy, and behavioral data into actionable insights. Founded by Ryan Magnussen in 2022, it raised roughly $4.6M-$5.6M in seed funding from investors including Aubrey Marcus and James Foster.
Sam Clark
Sam Clark, MD, PhD, is the founder and CEO of Terran Biosciences, a CNS-focused platform biotech he started in 2017 from his medical school dorm room with $10,000. A neuroscientist trained at MIT and Columbia, Clark has built one of the largest psychedelic development programs in the industry, is the named inventor on more than 200 patent applications, and holds the world's first patents for new forms of psilocybin and MDMA. Terran pairs a medicinal-chemistry drug design engine with an FDA-cleared neuroimaging software platform and a pipeline of late-stage assets licensed from Sanofi and Pierre Fabre.
John Ramunas
John Ramunas, PhD, is the Co-Founder and CEO of Rejuvenation Technologies Inc., a Mountain View, CA biotechnology company pioneering mRNA-based telomere extension therapy to reverse cellular aging. A serial entrepreneur turned neuroscientist, Ramunas spent his PhD at Stanford's Baxter Laboratory for Stem Cell Biology inventing the first safe, nonimmunogenic TERT mRNA drug - a technology now protected by 50+ patents. His company, backed by Khosla Ventures and Y Combinator, is advancing a pipeline targeting fatal orphan diseases including idiopathic pulmonary fibrosis and liver cirrhosis, with the long-term vision of a single therapy taken every few years to prevent age-related disease.
Fundamental Research Labs
Fundamental Research Labs (formerly Altera) is a San Francisco applied AI research company building autonomous, socially intelligent agents - what it calls 'digital human beings.' Founded by former MIT computational neuroscientist Dr. Robert Yang, the company ships consumer and prosumer products including Shortcut (a superhuman Excel agent) and Fairies (a general-purpose AI assistant), and raised a $33M Series A in August 2025 led by Prosus Ventures.
Trace Neuroscience
Trace Neuroscience is a South San Francisco biopharmaceutical company developing genomic medicines for neurodegenerative diseases, starting with ALS. Its lead program, TRCN-1023, is an antisense oligonucleotide designed to restore UNC13A protein function - a target genetically validated in roughly 97% of people living with ALS - by correcting the faulty RNA splicing caused by TDP-43 dysfunction. The company launched in November 2024 with a $101 million Series A led by Third Rock Ventures and entered the clinic in 2026.
Aagya Mathur
Aagya Mathur is the co-founder and CEO of Aavia, a Brooklyn-based hormone health company whose app helps people with ovaries understand how their cycle shapes their energy, mood, sleep and focus. A University of Virginia neuroscientist turned MIT Sloan MBA and ex-Deloitte consultant, she co-built Aavia out of an MIT bootcamp into a top-charting wellness app that has reached hundreds of thousands of users on organic growth alone, with backers ranging from MIT delta v to a $9.7M+ funding base.
Christin Glorioso
Christin Glorioso, MD, PhD, is a physician-scientist and serial entrepreneur who is CEO and co-founder of NeuroAge Therapeutics, a San Francisco brain-health company building AI-powered 'aging clocks' for the human brain. Trained at MIT and the Carnegie Mellon/University of Pittsburgh Medical Scientist Training Program, she spent two decades studying how brains age before leaving academia to turn that research into a diagnostic and drug-development engine. NeuroAge combines MRI brain-volume data, cognitive testing and proprietary RNA blood biomarkers - validated on data from more than 500,000 people - to estimate brain age and dementia risk decades before symptoms. She also founded the nonprofit Longevity Global and led the world's top-ranked US COVID-19 forecasting model in the XPRIZE Pandemic Response Challenge.
Meredith Perry
Meredith Perry is the co-founder and CEO of Elemind, a neurotech company building a wearable headband that reads your brainwaves in real time and nudges them with bursts of sound, marketed as sleep on demand. Before Elemind she was the inventor behind uBeam, the ultrasonic wireless-charging venture she dreamed up as a University of Pennsylvania undergrad and grew into a roughly $40 million, much-debated startup backed by Founders Fund, Andreessen Horowitz, Mark Cuban and Marissa Mayer. A trained paleobiologist and astrobiologist who once did research with NASA, Perry holds dozens of patents and now wants to build what she calls an app store for the brain.
MJ Antonini
MJ Antonini is the co-founder and CEO of NeuroBionics, an MIT spinout building hair-thin, flexible bioelectronic fibers that thread through blood vessels to reach deep neural structures - delivering deep brain stimulation without opening the skull. A Harvard-MIT Health Sciences and Technology graduate who trained in both medicine and engineering, he turned a decade of fiber research from Polina Anikeeva's MIT lab into a venture-backed company that raised an oversubscribed $10M seed round to push toward first-in-human trials.
Raj Amin
Raj Amin is the co-founder and CEO of Arcade Therapeutics, a New York science-first game studio building prescription digital therapeutics that embed clinically proven anxiety-reduction techniques inside mobile games. A University of Pennsylvania-trained engineer and Wharton MBA, he has spent more than two decades building venture-backed companies at the seam of healthcare, media and technology - including HealthiNation, the first on-demand consumer health video network, and Mana Health, a health-data interoperability platform later acquired by Comcast. He is a self-described #GirlDad, a drummer and aspiring guitarist, and a Broadway investor who has backed Tony Award-winning productions.